Aquestive Therapeutics (AQST) Interest Expenses: 2017-2025
Historic Interest Expenses for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $2.8 million.
- Aquestive Therapeutics' Interest Expenses fell 0.04% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 4.76%. This contributed to the annual value of $11.1 million for FY2024, which is 75.51% up from last year.
- Aquestive Therapeutics' Interest Expenses amounted to $2.8 million in Q3 2025, which was down 0.07% from $2.8 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Interest Expenses registered a high of $2.8 million during Q3 2021, and its lowest value of $1.3 million during Q3 2023.
- Moreover, its 3-year median value for Interest Expenses was $2.8 million (2025), whereas its average is $2.3 million.
- Its Interest Expenses has fluctuated over the past 5 years, first slumped by 41.40% in 2022, then soared by 121.34% in 2024.
- Quarterly analysis of 5 years shows Aquestive Therapeutics' Interest Expenses stood at $1.7 million in 2021, then decreased by 5.39% to $1.6 million in 2022, then soared by 37.76% to $2.3 million in 2023, then grew by 22.26% to $2.8 million in 2024, then declined by 0.04% to $2.8 million in 2025.
- Its last three reported values are $2.8 million in Q3 2025, $2.8 million for Q2 2025, and $2.8 million during Q1 2025.